help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gordon, K.
Right arrow Articles by Hodgen, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gordon, K.
Right arrow Articles by Hodgen, G. D.

Journal of Clinical Endocrinology & Metabolism, Vol 73, 1262-1268, Copyright © 1991 by Endocrine Society


ARTICLES

Suppression of ovarian estradiol secretion by a single injection of antide in cynomolgus monkeys during the early follicular phase: immediate, sustained, and reversible actions

K Gordon, RF Williams, DR Danforth, PM Conn, JS Hutchison and GD Hodgen
Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk 23510.

We examined the effects of the GnRH antagonist antide on ovarian estrogen secretion after a single administration in intact cycling cynomolgus monkeys (n = 5/group) during the early follicular phase. Antide treatment on menstrual cycle day 2 resulted in a dose-dependent increase in menstrual cycle lengths (mean +/- SEM) to 38 +/- 3, 49 +/- 8, and 96 +/- 15 days for 3.0, 10.0, and 30.0 mg/kg antide, respectively, in association with inhibition of folliculogenesis and suppression of estradiol concentrations to therapeutic levels. Subsequent resumption of apparently normal ovulatory menstrual cycles occurred in all 15 individuals. In addition, all four monkeys from the group treated with 30 mg/kg antide that were available for subsequent matings became pregnant and had normal babies. Thus, no irreversible consequences or adverse effects of antide on reproductive function in these primates was observed. No allergic or other adverse reactions were found locally or systemically in these primates, even at the highest dose of antide. To the extent that this primate model is a paradigm for clinical therapeutics, a single treatment of antide (30 mg/kg) provides sustained inhibition of ovarian estradiol secretion for about 2 months, thus demonstrating the feasibility of using antide for clinical management of steroid-dependent conditions.


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
P. Morales, C. Pasten, and E. Pizarro
Inhibition of In Vivo and In Vitro Fertilization in Rodents by Gonadotropin-Releasing Hormone Antagonists
Biol Reprod, October 1, 2002; 67(4): 1360 - 1365.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P. Morales, B. Kerr, C. Oliva, E. Pizarro, and M. Kong
Gonadotrophin-releasing hormone antagonists inhibit sperm binding to the human zona pellucida
Hum. Reprod., August 1, 1999; 14(8): 2069 - 2074.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society